Hide metadata

dc.date.accessioned2023-02-18T17:57:34Z
dc.date.available2023-02-18T17:57:34Z
dc.date.created2022-09-21T09:11:55Z
dc.date.issued2022
dc.identifier.citationØverberg, Linda Thøring Lugg, Elise Fritsch Gaarder, Mona Langhammer, Birgitta Thommessen, Bente Rønning, Ole Morten Morland, Cecilie . Plasma levels of BDNF and EGF are reduced in acute stroke patients. Heliyon. 2022, 8(6), 1-10
dc.identifier.urihttp://hdl.handle.net/10852/100144
dc.description.abstractStroke affects almost 14 million people worldwide each year. It is the second leading cause of death and a major cause of acquired disability. The degree of initial impairment in cognitive and motor functions greatly affects the recovery, but idiosyncratic factors also contribute. These are largely unidentified, which contributes to making accurate prediction of recovery challenging. Release of soluble regulators of neurotoxicity, neuroprotection and repair are presumably essential. Here we measured plasma levels of known regulators of neuroprotection and repair in patients with mild acute ischemic stroke and compared them to the plasma levels in healthy age and gender matched controls. We found that the levels of BDNF and EGF were substantially lower in stroke patients than in healthy controls, while the levels of bFGF and irisin did not differ between the groups. The lower levels of growth factors highlight that during the acute phase of stroke, there is a mismatch between the need for neuroprotection and repair, and the brain's ability to induce these processes. Large individual differences in growth factor levels were seen among the stroke patients, but whether these can be used as predictors of long-term prognosis remains to be investigated.
dc.languageEN
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titlePlasma levels of BDNF and EGF are reduced in acute stroke patients
dc.title.alternativeENEngelskEnglishPlasma levels of BDNF and EGF are reduced in acute stroke patients
dc.typeJournal article
dc.creator.authorØverberg, Linda Thøring
dc.creator.authorLugg, Elise Fritsch
dc.creator.authorGaarder, Mona
dc.creator.authorLanghammer, Birgitta
dc.creator.authorThommessen, Bente
dc.creator.authorRønning, Ole Morten
dc.creator.authorMorland, Cecilie
cristin.unitcode185,15,23,30
cristin.unitnameSeksjon for farmakologi og farmasøytisk
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin2053747
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Heliyon&rft.volume=8&rft.spage=1&rft.date=2022
dc.identifier.jtitleHeliyon
dc.identifier.volume8
dc.identifier.issue6
dc.identifier.doihttps://doi.org/10.1016/j.heliyon.2022.e09661
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn2405-8440
dc.type.versionPublishedVersion
cristin.articleide09661


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International